8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 15, 2006)

Filed February 15, 2006For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed a Form 8-K on February 15, 2006, to announce its financial results for the fourth quarter and full year ended December 31, 2005. This filing primarily serves to provide investors with an update on the company's financial performance and condition as of that date. The information provided in this 8-K, including the attached press release (Exhibit 99.1), is crucial for investors to understand Alnylam's financial standing and operational progress. While the specific financial figures are detailed within the press release, the filing itself confirms the reporting of these results and directs investors to the comprehensive details. Investors should review the accompanying press release for specifics on revenue, expenses, net loss, and cash position. This announcement is a key event for tracking the company's financial trajectory and its ability to fund its research and development activities in the rapidly evolving RNA interference therapeutics sector.

Key Highlights

  • 1Announcement of financial results for the quarter and year ended December 31, 2005.
  • 2Filing is primarily an announcement of financial performance, with detailed results contained in an attached press release (Exhibit 99.1).
  • 3Confirms the date of the financial results announcement as February 15, 2006.
  • 4The information furnished is not deemed 'filed' for purposes of Section 18 of the Exchange Act, but is provided for investor information.
  • 5The filing directs investors to Exhibit 99.1 for the full text of the press release announcing the financial results.
  • 6John M. Maraganore, President and Chief Executive Officer, signed the report.
  • 7Company is incorporated in Delaware and has its principal executive offices in Cambridge, MA.

Frequently Asked Questions

The main purpose of this Form 8-K filing is to announce Alnylam Pharmaceuticals, Inc.'s financial results for the quarter and full year ended December 31, 2005, and to provide investors with access to the press release containing these results.

The detailed financial results are provided in the press release dated February 15, 2006, which is included as Exhibit 99.1 to this Form 8-K filing.

This specific Form 8-K filing is primarily focused on the announcement of financial results. Any operational or strategic updates would be detailed within the accompanying press release (Exhibit 99.1).

No, the information in this Form 8-K, including the press release, is furnished and not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated by reference into another filing.